Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-05-10

Clinical Trial Update: A Research Study To Test How Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given By Subcutaneous Injection (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen) [Phase 1]

View source ↗

Summary

This is a Phase 1 trial comparing Filgrastim Hospira to Neupogen in healthy subjects given subcutaneous injections. The study evaluates pharmacokinetics and saf…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Filgrastim Hospira (filgrastim)
  • Neupogen (Filgrastim)

Snippet

Sponsor: Pfizer | Conditions: Neutropenia (Low White Blood Cell Count) | Phase 1 | Status: COMPLETED